Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Autolus Therapeutics logo — Focused on the development of precisely targeted, controlled...

Autolus Therapeutics

Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer

Founded 2014 United Kingdom London, United Kingdom 720 employees Post-IPO Equity Total: $1.07B Biopharma, Biotechnology +1

General Information

Company Name Autolus Therapeutics
Founded Year 2014
Location United Kingdom London, United Kingdom
Founders / Decision Makers
Team member
Employees 720
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Business Model B2B, B2D
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Autolus Therapeutics. To contact Autolus Therapeutics, visit autolus.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Autolus Therapeutics compare?

A PDF of Autolus Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Autolus Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Autolus Therapeutics

Autolus Therapeutics, founded in 2014, is a pioneering company in the Biopharma, Biotechnology, and Pharmaceutical industries. Based in the United Kingdom, the company is renowned for its innovative approach towards cancer treatment, with a clear focus on developing precisely targeted and highly controlled T cell therapies.

The company's technology centers on advanced autologous CAR T cell therapies, which leverage comprehensive programming capabilities to potentially deliver life-altering treatments for patients with cancer and autoimmune diseases. This approach aligns with their slogan, which emphasizes precision and activity in targeting cancer cells.

In their recent financial move, Autolus Therapeutics secured a substantial investment of $350.00M through a Post-IPO Equity, as of February 8, 2024. This substantial capital injection evidences strong investor confidence and provides the company with resources to advance its therapeutic developments and uphold its growth trajectory.

Business keywords: CAR T cell therapy, T cell programming, Cancer treatment, Autologous T cell therapies, Next-generation therapies, Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, AUTO8, Autoimmune disease treatment, Biopharmaceuticals, Therapeutic pipeline

Services & Products

Development of autologous T cell therapies
Advanced cell programming
Manufacturing of T cells
Clinical trial management
Pipeline products for cancer and autoimmune diseases

Target Customers

Patients with cancer and autoimmune diseases Healthcare professionals Investors interested in biotech innovations Research institutions

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $350.00M -
08 Feb 2024
Post IPO Equity £122.50M -
08 Dec 2022
Post IPO Equity $250.00M 1
Blackstone Group
Blackstone Group
08 Nov 2021
Post IPO Equity $100.00M -
10 Feb 2021
Post IPO Equity Undisclosed 1
PPF Group
PPF Group
17 Sep 2019
Post IPO Equity $100.00M -
11 Apr 2019
Post IPO Equity Undisclosed 1
4BIO Capital
4BIO Capital
01 Jan 2018
Series C $80.00M 7
GV Arix Bioscience Nextech Invest
GV, Arix Bioscience +5
26 Sep 2017
Series B £40.00M 2
Arix Bioscience Woodford Patient Capital Trust
Arix Bioscience, Woodford Patient Capital Trust
03 Mar 2016
Series A £30.00M 1
Syncona Investment Management
Syncona Investment Management
22 Jan 2015

Autolus Therapeutics Alternatives & Competitors

View All Alternatives
Autolus Therapeutics vs
Adicet Bio, Inc
Adicet Bio, Inc United States

A biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell...

IPO
124 employees
Biopharma, Biotechnology
Compare Autolus Therapeutics vs Adicet Bio, Inc
Autolus Therapeutics vs
Adaptimmune
Adaptimmune United Kingdom

Designing and delivering cell therapies to transform the lives of people with cancer.

Post-IPO Debt
200 employees
Biopharma, Biotechnology
Compare Autolus Therapeutics vs Adaptimmune
Autolus Therapeutics vs
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. United States

Plans to develop a novel format for T-cell mediated anti-tumour therapy

IPO
47 employees
Biotechnology, Pharmaceutical
Also compare with: Autolus Therapeutics vs Be Biopharma Be Biopharma View all alternatives

FAQ About Autolus Therapeutics

Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer
Autolus Therapeutics was founded in 2014.
Autolus Therapeutics is headquartered in London, United Kingdom.
Autolus Therapeutics operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on CAR T cell therapy, T cell programming, Cancer treatment and Autologous T cell therapies. Its customers include Patients with cancer and autoimmune diseases, Healthcare professionals and Investors interested in biotech innovations.
Autolus Therapeutics has a B2B and B2D business model. Its revenue comes from Product Sales and Licensing.
Autolus Therapeutics has approximately 720 employees.
Autolus Therapeutics has completed 10 funding rounds, raising a total of $1.07B. The latest funding stage is Post-IPO Equity.
Autolus Therapeutics offers: Development of autologous T cell therapies, Advanced cell programming, Manufacturing of T cells, Clinical trial management, Pipeline products for cancer and autoimmune diseases.
Top alternatives and competitors to Autolus Therapeutics include Adicet Bio, Inc, Adaptimmune, Bolt Biotherapeutics, Inc., 3T Biosciences, Umoja Biopharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Autolus Therapeutics and Adicet Bio, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Autolus Therapeutics, https://bouncewatch.com/company/autolus, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes